Introduction
============

Lung cancer is the leading cause of cancer-related mortality worldwide.[@b1-ott-10-3557] Non-small-cell lung cancer (NSCLC) comprises \~85% of all lung cancer patients.[@b2-ott-10-3557] Among patients with NSCLC, \~70% present with locally advanced nonresectable disease (stage IIIB)[@b3-ott-10-3557] or metastatic disease (stage IV),[@b4-ott-10-3557] which means that these patients will have a median survival time of 4--5 months since diagnosis and only 10% of them will survive for 1 year.[@b5-ott-10-3557],[@b6-ott-10-3557] For patients with advanced-stage NSCLC, chemotherapy with a platinum doublet offers the median overall survival (OS) of 10 months.[@b7-ott-10-3557] Recent introduction of molecularly targeted therapies for NSCLC resulted in clinically meaningful OS improvements. However, only selected patients whose tumors exhibit specific oncogene addiction can benefit from the targeted therapies.[@b8-ott-10-3557] Unfortunately, almost all patients eventually acquire resistance to targeted therapies.[@b9-ott-10-3557]--[@b11-ott-10-3557] Therefore, lung cancer remains a disease with dismal prognosis, and novel therapies focused on new target are urgently needed.

In tumor immunology, the basic function of the host immune system is to differentiate between normal cells and cancer cells to protect the body from the damage caused by the cancer cells.[@b12-ott-10-3557] T cells play a key role in cell-mediated immunity. During the immune response, however, some of the transformed cancer cells employ several immune evasion strategies to generate an immunosuppressive microenvironment to overcome the immune response, resulting in tumor progression.[@b13-ott-10-3557]--[@b17-ott-10-3557] The most important mechanism of immune tolerance by which cancer cells escape the immune system is to diminish local tryptophan (Trp) by indoleamine 2,3-dioxygenase (IDO).[@b18-ott-10-3557],[@b19-ott-10-3557]

IDO is a key enzyme that catalyzes the initial and rate-limiting steps in the Trp degradation along the kynurenine (Kyn) pathway to form Kyn, which is converted into several metabolites through downstream enzymes.[@b20-ott-10-3557] For many years, IDO has been known as an innate defense mechanism, limiting the growth of viruses, bacteria, and intracellular pathogens by consuming Trp in the local microenvironment.[@b21-ott-10-3557],[@b22-ott-10-3557] IDO activity can be quantified by measuring the serum Kyn-to-Trp (Kyn/Trp) ratio using high-performance liquid chromatography (HPLC) because Kyn is the first product formed through catabolizing Trp, which is tightly regulated by IDO. Therefore, a high Kyn/Trp ratio reflects an enhanced IDO activity.[@b23-ott-10-3557]--[@b26-ott-10-3557]

Increased expression of IDO has been observed in wide range of types of human solid tumors, such as colorectal, breast, ovarian, and lung cancers and melanoma,[@b27-ott-10-3557]--[@b31-ott-10-3557] as well as in hematological malignancies, including acute myeloid leukemia[@b32-ott-10-3557] and lymphoma.[@b33-ott-10-3557] Within the tumor microenvironment, constitutive expression of IDO, which is expressed by cancer cells as well as by some tumor infiltrating cells, for example, dendritic cells (DCs),[@b18-ott-10-3557],[@b27-ott-10-3557],[@b34-ott-10-3557],[@b35-ott-10-3557] can be detected in the peritumoral stroma and in tumor-draining lymph nodes.[@b34-ott-10-3557],[@b36-ott-10-3557] IDO induces peripheral immunotolerance and immunosuppression by the following mechanisms: 1) reducing the local concentration of Trp and starving T cells from the important amino acid, resulting in the inhibition of T-cell proliferation,[@b37-ott-10-3557]--[@b39-ott-10-3557] 2) producing immunomodulatory toxic metabolites, such as Kyn (kynurenic acid \[Kyna\]), which efficiently suppress the function of T cells, render T cells more sensitive to apoptosis, and promote the differentiation of naive T cells into regulatory T cells (Tregs) that can directly inhibit the host immune response,[@b18-ott-10-3557],[@b20-ott-10-3557],[@b27-ott-10-3557],[@b40-ott-10-3557]--[@b42-ott-10-3557] and 3) secreting immunosuppressive cytokines, such as IL-10 and TGF-β, to protect tumor form host immunity.[@b43-ott-10-3557],[@b44-ott-10-3557] To date, a large number of studies have shown that high expression of IDO is predictive of shorten survival in a variety of human malignancies, including solid tumors (lung,[@b34-ott-10-3557],[@b45-ott-10-3557],[@b46-ott-10-3557] colorectal,[@b47-ott-10-3557]--[@b49-ott-10-3557] endometrial,[@b50-ott-10-3557],[@b51-ott-10-3557] ovarian,[@b52-ott-10-3557]--[@b55-ott-10-3557] hepatocellular,[@b56-ott-10-3557] and breast[@b57-ott-10-3557]--[@b60-ott-10-3557] cancers, malignant melanoma,[@b61-ott-10-3557],[@b62-ott-10-3557] gynecological,[@b63-ott-10-3557] cervical,[@b64-ott-10-3557],[@b65-ott-10-3557] esophageal,[@b66-ott-10-3557]--[@b68-ott-10-3557] and pancreatic ductal[@b69-ott-10-3557] cancers, osteosarcoma,[@b70-ott-10-3557] and brain cancer[@b71-ott-10-3557]) and various hematological tumors, such as myeloma,[@b72-ott-10-3557] leukemia,[@b73-ott-10-3557]--[@b77-ott-10-3557] and lymphoma.[@b33-ott-10-3557],[@b78-ott-10-3557]--[@b80-ott-10-3557]

In several preclinical studies, the IDO-blocking agent 1-methyl-Trp (1-MT) has shown remarkable ability to inhibit IDO activity and cooperate with cytotoxic chemotherapeutic agents in inhibiting the growth of cancer cells in animal models.[@b81-ott-10-3557],[@b82-ott-10-3557]

Although the above studies suggest critical relationship between IDO and disease progression in cancer, there have been no studies focusing on the relationship among the activity of IDO, clinical parameters, and response to chemotherapy in patients with stage IIIB or IV NSCLC. The present study measured the serum concentrations of Trp and Kyn by HPLC and estimated the IDO activity in advanced NSCLC patients. The object of our study is to clarify the correlation between the status of suppression in lung cancer patients and the clinical characteristics as well as the response to chemotherapy of the selected patients so that we can improve the poor prognosis of these patients.

Subjects and methods
====================

Subjects
--------

A total of 252 patients, of whom 155 were men and 97 were women, were enrolled at our institutions from May 2015 to September 2016. The main inclusion criteria were as follows: 1) cytologically or histologically confirmed primary NSCLC; 2) stage IIIB or IV according to the seventh TNM stage classification system; 3) no anticancer treatment before the enrollment of the study, including surgery, chemotherapy, target agents, and immunotherapy; 4) patients with a computed tomography (CT) or positron-emission tomography (PET) or magnetic resonance imaging (MRI) scan of evaluable primary lesions before the first cycle and third cycle of chemotherapy; and 5) Karnofsky Performance Status (KPS) scale of 60 and 100 and requirement of adequate organ, bone marrow, liver, and renal functions. The main exclusion criteria are as follows: 1) autoimmune disease, viral hepatitis, or acquired immunodeficiency syndrome (AIDS); 2) pregnant women; and 3) the other types of carcinoma. Histological types were classified according to the World Health Organization (WHO) criteria. The study subjects also included 55 healthy blood donors serving as a control group (32 men and 23 women). Healthy subjects with recent infection, immune system disease, and malignant tumors were excluded. This study was approved by the Ethics Committee of Shandong Cancer Hospital, who deemed written informed consent unnecessary as the experiments did not violate relevant rules of experimental ethics.

Treatment schedule
------------------

The chemotherapy regimens were used according to the histological types. Treatment schedules consisted of at least two cycles of pemetrexed (500 mg/m^2^) combined with cisplatin (75 mg/m^2^) or carboplatin (AUC =5--6) or nedaplatin (80 mg/m^2^) or lobaplatin (50 mg/m^2^); docetaxel (75 mg/m^2^) combined with cisplatin or carboplatin or nedaplatin; gemcitabine (1,250 mg/m^2^) combined with cisplatin or carboplatin or nedaplatin or lobaplatin; and etoposide (100 mg/m^2^) combined with cisplatin. Among them, some patients with lung adenocarcinoma were administered with bevacizumab (15 mg/kg) combined with chemotherapy agents.

Evaluation of response concerning the primary site
--------------------------------------------------

All the patients are required to have imaging examinations for the primary sites before the first cycle and third cycle of chemotherapy. Tumor responses were assessed as follows: complete response (CR) for the primary lesion was defined as the complete disappearance of all measurable and assessable target lesions for \>4 weeks; partial response (PR) was defined as at least 30% decrease in the sum of diameters of target lesions; progressive disease (PD) was defined as a ≥20% enlargement of the tumor or the appearance of a new tumor lesion; and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Measurements of serum Trp and Kyn
---------------------------------

For the patients with advanced NSCLC, venous blood samples were collected from peripheral vein after at least 12 hours of fasting before the first cycle of chemotherapy. For the healthy subjects, blood samples were collected from peripheral vein after at least 12 hours of fasting. Blood samples were centrifuged, and the separated serum samples were deep frozen and stored at -80°C immediately until further analysis. After thawing at room temperature, 200 µL of samples were acidified with 200 µL perchloric acid. Then, the samples were centrifuged for 10 minutes (10,000 rpm, 4°C), and the supernatants were centrifuged under the same conditions again for the purpose of removing precipitated proteins completely. Analyses were separated by an isocratic elution of the injected samples. Eluted Trp and Kyn was subjected to HPLC (Shimadzu LC-20A HPLC system: C18 reverse-phase column) and quantified fluorometrically (Shimadzu RF-20A fluorescence detector). Concentrations of Trp and Kyn were determined by HPLC as previously described.[@b54-ott-10-3557] To estimate the IDO activity, the Kyn/Trp ratio was calculated.[@b83-ott-10-3557]

Statistical analysis
--------------------

All continuous variables were assessed for normality of the distribution using the P--P plot. For the data that fitted normal distribution, it was presented as the mean value and standard deviation and analyzed by independent-samples *t*-test or one-way ANOVA. In case of skewed distributions, the median and interquartile ranges (IQRs, 25th--75th percentile) were presented and statistical analysis was performed using the nonparametric Kruskal--Wallis test or Mann--Whitney *U* test. Spearman rank correlation analysis was applied to assess correlations. *P*\<0.05 was considered as statistically significant. Analyses were performed using the software package, version 23.0 for Windows (IBM Corporation, Armonk, NY, USA).

Results
=======

Clinical characteristics
------------------------

A group of 252 cytologically or histologically proven NSCLC patients with a mean age of 57.9±10.4 years and 55 healthy subjects with a mean age of 60.1±10.5 years was evaluated. The clinical characteristics of the subjects are listed in [Table 1](#t1-ott-10-3557){ref-type="table"}. No age and gender differences were observed between healthy controls and lung cancer patients (*P*\>0.05). Among the patients, 54 patients were diagnosed at stage IIIB and 198 patients were diagnosed at stage IV. A total of 185 patients had lung adenocarcinoma, and the others had nonadenocarcinoma (52 squamous cell carcinoma, 8 large cell carcinoma, 4 atypical carcinoid, and 3 adenosquamous cell carcinoma). As for the response to chemotherapy, no one reached CR, 122 patients reached PR and 109 patients had SD, whereas 21 patients progressed after two cycles of chemotherapy.

Serum Trp and Kyn and IDO activity in patients and controls
-----------------------------------------------------------

The serum concentrations of Trp and Kyn and the IDO activity are presented in [Table 2](#t2-ott-10-3557){ref-type="table"}. Trp concentrations in patients were significantly lower compared to those in healthy individuals (*P*\<0.0001). Lung cancer patients had significantly higher Kyn concentrations (*P*\<0.0001) and IDO activity (*P*\<0.0001) than healthy controls.

Correlation of serum Trp and Kyn and IDO activity with clinical characteristics
-------------------------------------------------------------------------------

Patients with lung adenocarcinoma had significantly lower concentration of Trp (*P*=0.017) and higher IDO activity (*P*=0.006) with slightly higher concentration of Kyn but not significantly different (*P*=0.268) than the patients with nonadenocarcinoma ([Table 3](#t3-ott-10-3557){ref-type="table"}). However, we did not explore the difference between the patients with nonadenocarcinoma due to the limited sample size. Interestingly, comparing patients with stage IIIB disease, significant decreases in serum concentrations of Trp (*P*=0.018) and increases in IDO activity (*P*=0.012) were found in patients with stage IV disease, whereas the Kyn concentration did not reach statistical significance ([Table 4](#t4-ott-10-3557){ref-type="table"}).

We also explored the differences between the smoking status and KPS scale with the concentrations of Trp and Kyn and IDO activity; no significant differences were observed. In addition, no correlation between patient's age and concentrations of Trp or Kyn as well as the IDO activity was observed.

Correlation of serum Trp and Kyn and IDO activity with responses to chemotherapy
--------------------------------------------------------------------------------

The PR patients had significantly lower concentrations of Trp with significantly higher concentrations of Kyn, resulting in higher IDO activity compared to the SD patients (*P*\<0.0001) and PD patients (*P*\<0.0001). However, there are no differences between the SD patients and the PD patients concerning the concentrations of Trp and Kyn and IDO activity ([Table 5](#t5-ott-10-3557){ref-type="table"} and [Figure 1](#f1-ott-10-3557){ref-type="fig"}).

Discussion
==========

Our study, for the first time, measured the pretreatment serum concentrations of Trp and Kyn by HPLC and estimated the activity of IDO through calculating Kyn/Trp ratio in patients with locally advanced or metastatic NSCLC. This study showed an accelerated Trp catabolism in NSCLC patients than in healthy controls, which was consistent with previous observations in lung cancer,[@b45-ott-10-3557],[@b84-ott-10-3557],[@b85-ott-10-3557] gynecologic cancer,[@b86-ott-10-3557] breast cancer,[@b87-ott-10-3557] malignant melanoma,[@b61-ott-10-3557] colorectal cancer,[@b49-ott-10-3557] thyroid cancer,[@b88-ott-10-3557] leukemia,[@b75-ott-10-3557],[@b76-ott-10-3557] esophageal cancer,[@b66-ott-10-3557],[@b89-ott-10-3557] and ovarian cancer.[@b90-ott-10-3557] There are several explanations for this result. The most important reason is that the IDO expressed constitutively by cancer cells and some other cells starve T cells from the important amino acid, Trp, causing them to be incapable of performing an appropriate immune response.[@b18-ott-10-3557] The other potential reason for this phenomenon is that patients with cancer reduce dietary intake of this essential amino acid, whereas the cancer cells still consume Trp in the tumor microenvironment to protect them from the immunosurveillance.

Sagan et al[@b91-ott-10-3557] found that Kyna level in the serum of patients with adenocarcinoma was significantly higher than that in the serum of patients with squamous cell cancer (*P*\<0.05). Kyna is the end-stage product of the transamination side branch in the Kyn pathway.[@b18-ott-10-3557],[@b92-ott-10-3557],[@b93-ott-10-3557] Therefore, the level of Kyna can reflect the activity of Kyn pathway; in other words, it can reflect the activity of IDO. Previous studies have shown that lung adenocarcinoma is characterized by more aggressive development, resulting in poorer prognosis compared to other histological types of NSCLC.[@b94-ott-10-3557]--[@b96-ott-10-3557] This characteristic of invasiveness of lung adenocarcinoma may be attributed to the properties of the tumor itself, as well as to impaired antitumor immune response.[@b97-ott-10-3557],[@b98-ott-10-3557] Supporting the above theory, our data showed that the degradation of Trp and high level of IDO activity were observed in patients with adenocarcinoma than in patients with nonadenocarcinoma.

We also found that patients with metastatic lung cancer had significantly higher IDO activity than those with locally advanced lung cancer. Similarly, Suzuki et al[@b45-ott-10-3557] reported that an increased IDO activity was discovered in advanced stages of lung cancer than in early stages of lung cancer. However, Karanikas et al[@b46-ott-10-3557] found no significant correlation between disease stages and mRNA IDO expression by tumor tissues in 28 patients with NSCLC. This conflict may be partially attributed to the different sample sizes and methods to assess IDO expression or activity between these studies. Our results were also consistent with previous studies, which found that high expression of IDO has been associated with high frequencies of metastasis in patients with hepatocellular carcinoma,[@b56-ott-10-3557] endometrial tumors,[@b51-ott-10-3557] and colorectal cancer.[@b47-ott-10-3557] These results indicate that IDO activity is enhanced in patients with a larger tumor burden.

Our study discovered that there was a significant difference between the PR patients and the SD and PD patients, whereas no significant difference was found between the SD patients and the PD patients. Previous studies[@b81-ott-10-3557] suggested that IDO might be associated with resistance to chemotherapeutic agents, which was consistent with another report showing that IDO was involved in paclitaxel resistance in ovarian cancer.[@b52-ott-10-3557]

Consequently, IDO may serve as an important target for anticancer agents. To our knowledge, several small-molecule IDO inhibitors, such as 1-MT, show effective antitumor activity in animal models, especially when they are combined with cytotoxic chemotherapeutic agents, such as platinum compounds, taxane derivatives, and cyclophosphamide. The IDO inhibitors reactivate the T cells by suppressing the consumption of Trp and the production of Kyn to block the immune escape without increased toxicity.[@b81-ott-10-3557],[@b82-ott-10-3557],[@b99-ott-10-3557],[@b100-ott-10-3557] Furthermore, 1-MT has been evaluated in clinical trials to disrupt tumor tolerance in cancer patients to improve the immunosuppression status and postpone the growth of the tumor.[@b101-ott-10-3557]

Study limitations
=================

However, there are several limitations of the present study, which should be discussed. First, the small sample size might impair the effectiveness of our results and a more robust sample size may have improved the power to detect significant differences between the levels of Trp and Kyn and IDO activity and the clinical parameters as well as the response to chemotherapy. Second, we did not examine the concentrations of the Trp and Kyn and IDO activity after standard treatment. Therefore, we cannot figure out whether IDO activity changed by chemotherapy. In addition, this study did not perform survival analysis. As a result, we cannot give the conclusion whether levels of Trp and Kyn and IDO activity can serve as prognostic factors for stage IIIB or IV NSCLC patients.

Conclusion
==========

The present study presented that patients with stage IIIB or IV NSCLC had lower serum concentration of Trp and higher serum concentration of Kyn, resulting in more enhanced IDO activity than healthy controls, and that increased IDO activity related to the histological types and disease stages. The most important discovery of our study was that IDO activity differed significantly between the PR patients and the SD and PD patients. The result suggested that patients with an increased immunosuppression status induced by higher IDO activity might decrease the efficacy of chemotherapy. Taken together with previous studies, the combined treatment of IDO inhibitor and chemotherapy is effective in improving the immunosup-pression status and has potential clinical prospect.
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###### 

Comparison of serum concentrations of Trp (**A**) and Kyn (**B**) and IDO activity (**C**) between PR patients, SD patients, and PD patients.

**Notes:** (**A**) Serum Trp level in PR patients vs SD patients (*P*\<0.0001) and PR patients vs PD patients (*P*\<0.0001). (**B**) Serum Kyn level in PR patients vs SD patients (*P*\<0.0001) and PR patients vs PD patients (*P*\<0.0001). (**C**) Serum IDO activity in PR patients vs SD patients (*P*\<0.0001) and PR patients vs PD patients (*P*\<0.0001).

**Abbreviations:** Kyn, kynurenine; IDO, indoleamine 2,3-dioxygenase; Max, maximum; Min, minimum; PD, progressive disease; PR, partial response; SD, stable disease; Trp, tryptophan.
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###### 

Clinical characteristics of patients with non-small-cell lung cancer and healthy controls

  Characteristics                 Patients                                               \%[a](#tfn1-ott-10-3557){ref-type="table-fn"}   Controls                                               \%     *P*-value
  ------------------------------- ------------------------------------------------------ ----------------------------------------------- ------------------------------------------------------ ------ ------------
  Total                           252                                                    55                                                                                                            
  Sex                                                                                                                                                                                                  0.647 (ns)
   Male                           155                                                    61.5                                            32                                                     58.2   
   Female                         97                                                     38.5                                            23                                                     41.8   
  Age (years)                     57.9±10.4[b](#tfn2-ott-10-3557){ref-type="table-fn"}                                                   60.1±10.5[b](#tfn2-ott-10-3557){ref-type="table-fn"}          0.072 (ns)
  Smoking status                                                                                                                                                                                       
   Former/current smoker          128                                                    50.8                                                                                                          
   Never smoker                   124                                                    49.2                                                                                                          
  KPS scale                                                                                                                                                                                            
   ≥80                            240                                                    95.2                                                                                                          
   \<80                           12                                                     4.8                                                                                                           
  Stage                                                                                                                                                                                                
   Stage IIIB                     54                                                     21.4                                                                                                          
   Stage IV                       198                                                    78.6                                                                                                          
  Histological type                                                                                                                                                                                    
   Adenocarcinoma                 185                                                    73.4                                                                                                          
   Squamous cell carcinoma        52                                                     20.6                                                                                                          
   Large cell carcinoma           8                                                      3.2                                                                                                           
   Atypical carcinoid             4                                                      1.6                                                                                                           
   Adenosquamous cell carcinoma   3                                                      1.2                                                                                                           
  Response to chemotherapy                                                                                                                                                                             
   PR                             122                                                    48.4                                                                                                          
   SD                             109                                                    43.3                                                                                                          
   PD                             21                                                     8.3                                                                                                           

**Notes:**

The proportion of the numbers in the total patients.

Mean ± standard deviation.

**Abbreviations:** KPS, Karnofsky Performance Status; ns, not significant; PD, progressive disease; PR, partial response; SD, stable disease.

###### 

Serum concentrations of Trp and Kyn and IDO activity in patients and controls

  Variables      Patients                                                             Controls                  *P*-value
  -------------- -------------------------------------------------------------------- ------------------------- -----------
  Trp (µmol/L)   27.637 (16.966--42.217)[a](#tfn3-ott-10-3557){ref-type="table-fn"}   33.142 (28.614--47.527)   \<0.0001
  Kyn (µmol/L)   1.018 (0.760--1.356)                                                 0.411 (0.355--0.468)      \<0.0001
  IDO activity   0.0389 (0.0178--0.0741)                                              0.0111 (0.0091--0.0133)   \<0.0001

**Notes:**

Median and IQR (25th--75th).

**Abbreviations:** IQR, interquartile range; Kyn, kynurenine; IDO, indoleamine 2,3-dioxygenase; Trp, tryptophan.

###### 

Serum concentrations of Trp and Kyn and IDO activity in the different groups of histological types

  Variables      Adenocarcinoma                                                       Nonadenocarcinoma         *P*-value
  -------------- -------------------------------------------------------------------- ------------------------- -----------
  Trp (µmol/L)   25.072 (15.792--39.224)[a](#tfn5-ott-10-3557){ref-type="table-fn"}   32.059 (20.385--45.862)   0.017
  Kyn (µmol/L)   1.033 (0.762--1.400)                                                 0.929 (0.738--1.282)      0.268
  IDO activity   0.0449 (0.0189--0.0779)                                              0.0245 (0.0155--0.0563)   0.006

**Notes:**

Median and IQR (25th--75th).

**Abbreviations:** IQR, interquartile range; Kyn, kynurenine; IDO, indoleamine 2,3-dioxygenase; Trp, tryptophan.

###### 

Serum concentrations of Trp and Kyn and IDO activity in the different groups of disease stages

  Variables      Stage IIIB                                                           Stage IV                  *P*-value
  -------------- -------------------------------------------------------------------- ------------------------- -----------
  Trp (µmol/L)   33.051 (21.123--47.946)[a](#tfn7-ott-10-3557){ref-type="table-fn"}   26.320 (16.097--39.211)   0.018
  Kyn (µmol/L)   0.924 (0.747--1.258)                                                 1.041 (0.762--1.403)      0.223
  IDO activity   0.0225 (0.0158--0.0595)                                              0.0445 (0.0190--0.0757)   0.012

**Notes:**

Median and IQR (25th--75th).

**Abbreviations:** IQR, interquartile range; Kyn, kynurenine; IDO, indoleamine 2,3-dioxygenase; Trp, tryptophan.

###### 

Serum concentrations of Trp and Kyn and IDO activity in the different groups of responses to chemotherapy

  Variables      PR                                                                    SD                        PD                        *P*-value
  -------------- --------------------------------------------------------------------- ------------------------- ------------------------- -----------
  Trp (µmol/L)   35.536 (923.858--51.308)[a](#tfn9-ott-10-3557){ref-type="table-fn"}   19.941 (13.082--32.171)   20.287 (12.987--28.646)   \<0.0001
  Kyn (µmol/L)   0.889 (0.730--1.176)                                                  1.124 (0.783--1.554)      1.252 (0.914--1.654)      \<0.0001
  IDO activity   0.0240 (0.0155--0.0381)                                               0.0652 (0.0390--0.0831)   0.0868 (0.0209--0.0993)   \<0.0001

**Notes:**

Median and IQR (25th--75th).

**Abbreviations:** IQR, interquartile range; Kyn, kynurenine; IDO, indoleamine 2,3-dioxygenase; PD, progressive disease; PR, partial response; SD, stable disease; Trp, tryptophan.
